{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:06:03Z","timestamp":1791237963045,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"crossref","award":["2024AFB1035"],"award-info":[{"award-number":["2024AFB1035"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2021M692613"],"award-info":[{"award-number":["2021M692613"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Start-up Funding of Renmin Hospital of Wuhan University","award":["RMRCQD2023002"],"award-info":[{"award-number":["RMRCQD2023002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26956-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T15:48:15Z","timestamp":1764258495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["m6A regulators-based gene expression pattern is associated with immune microenvironment characteristics in hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Wenjuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erxiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunqiao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banlai","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianshan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"17","key":"26956_CR1","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3748\/wjg.v29.i17.2571","volume":"29","author":"F Villarruel-Melquiades","year":"2023","unstructured":"Villarruel-Melquiades, F. et al. Current and novel approaches in the Pharmacological treatment of hepatocellular carcinoma. World J. Gastroenterol. 29 (17), 2571\u20132599 (2023).","journal-title":"World J. Gastroenterol."},{"key":"26956_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/JHC.S44381","volume":"1","author":"MC Kew","year":"2014","unstructured":"Kew, M. C. Hepatocellular carcinoma: epidemiology and risk factors. J. Hepatocell Carcinoma. 1, 115\u2013125 (2014).","journal-title":"J. Hepatocell Carcinoma"},{"issue":"1","key":"26956_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.21037\/hbsn-21-75","volume":"12","author":"L An","year":"2023","unstructured":"An, L. et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in china: estimates based on data from 188 population-based cancer registries. Hepatobiliary Surg. Nutr. 12 (1), 45\u201355 (2023).","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"7","key":"26956_CR4","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/cancers15072070","volume":"15","author":"S Hagiwara","year":"2023","unstructured":"Hagiwara, S., Nishida, N. & Kudo, M. Advances in immunotherapy for hepatocellular carcinoma. Cancers (Basel). 15 (7), 2070 (2023).","journal-title":"Cancers (Basel)"},{"issue":"8","key":"26956_CR5","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.3390\/curroncol29080434","volume":"29","author":"MY Feng","year":"2022","unstructured":"Feng, M. Y., Chan, L. L. & Chan, S. L. Drug treatment for advanced hepatocellular carcinoma: First-Line and beyond. Curr. Oncol. 29 (8), 5489\u20135507 (2022).","journal-title":"Curr. Oncol."},{"issue":"3","key":"26956_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00432-022-04057-3","volume":"149","author":"W Wen","year":"2023","unstructured":"Wen, W., Zhang, Y., Zhang, H. & Chen, Y. Clinical outcomes of PD-1\/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 149 (3), 969\u2013978 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"26956_CR7","doi-asserted-by":"publisher","first-page":"151284","DOI":"10.1016\/j.ejcb.2022.151284","volume":"102","author":"N Minaei","year":"2023","unstructured":"Minaei, N. et al. Immunotherapeutic approaches in hepatocellular carcinoma: Building blocks of hope in near future. Eur. J. Cell. Biol. 102 (1), 151284 (2023).","journal-title":"Eur. J. Cell. Biol."},{"issue":"1","key":"26956_CR8","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.cellin.2022.100075","volume":"2","author":"J Liu","year":"2022","unstructured":"Liu, J., Huang, H., Zhang, M., Qing, G. & Liu, H. Intertwined regulation between RNA m6A modification and cancer metabolism. Cell. Insight. 2 (1), 100075 (2022).","journal-title":"Cell. Insight"},{"issue":"1","key":"26956_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-022-01704-8","volume":"22","author":"X Cao","year":"2023","unstructured":"Cao, X. et al. m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion. Mol. Cancer. 22 (1), 42 (2023).","journal-title":"Mol. Cancer"},{"issue":"12","key":"26956_CR10","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/diagnostics12122996","volume":"12","author":"M Ma","year":"2022","unstructured":"Ma, M. et al. N6-methyladenosine modification of noncoding rnas: mechanisms and clinical applications in cancer. Diagnostics (Basel). 12 (12), 2996 (2022).","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"26956_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An, Y. & Duan, H. The role of m6A RNA methylation in cancer metabolism. Mol. Cancer. 21 (1), 14 (2022).","journal-title":"Mol. Cancer"},{"issue":"6","key":"26956_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","volume":"164","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. N6-Methyladenosine-Mediated Up-Regulation of FZD10 regulates liver cancer stem cells\u2019 properties and lenvatinib resistance through WNT\/\u03b2-Catenin and Hippo signaling pathways. Gastroenterology 164 (6), 990\u20131005 (2023).","journal-title":"Gastroenterology"},{"key":"26956_CR13","doi-asserted-by":"publisher","first-page":"755206","DOI":"10.3389\/fonc.2021.755206","volume":"11","author":"N Qu","year":"2021","unstructured":"Qu, N. et al. Role of N6-Methyladenosine (m6A) methylation regulators in hepatocellular carcinoma. Front. Oncol. 11, 755206 (2021).","journal-title":"Front. Oncol."},{"key":"26956_CR14","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.aohep.2021.100538","volume":"25","author":"YF Wang","year":"2021","unstructured":"Wang, Y. F. et al. Dysregulated N6-methyladenosine (m6A) processing in hepatocellular carcinoma. Ann Hepatol. 25, 100538 (2021).","journal-title":"Ann Hepatol."},{"issue":"6","key":"26956_CR15","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1007\/s13577-022-00769-3","volume":"35","author":"J Hu","year":"2022","unstructured":"Hu, J. et al. METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma. Hum. Cell. 35 (6), 1838\u20131855 (2022).","journal-title":"Hum. Cell"},{"key":"26956_CR16","doi-asserted-by":"publisher","first-page":"687756","DOI":"10.3389\/fcell.2021.687756","volume":"9","author":"J Li","year":"2021","unstructured":"Li, J. et al. m6A Regulator-Associated modification patterns and immune infiltration of the tumor microenvironment in hepatocarcinoma. Front. Cell. Dev. Biol. 9, 687756 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"26956_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12957-021-02354-8","volume":"19","author":"J Cai","year":"2021","unstructured":"Cai, J., Zhou, M. & Xu, J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J. Surg. Oncol. 19 (1), 241 (2021).","journal-title":"World J. Surg. Oncol."},{"key":"26956_CR18","doi-asserted-by":"publisher","first-page":"707930","DOI":"10.3389\/fphar.2021.707930","volume":"12","author":"Y Du","year":"2021","unstructured":"Du, Y. et al. An m6A-Related prognostic biomarker associated with the hepatocellular carcinoma immune microenvironment. Front. Pharmacol. 12, 707930 (2021).","journal-title":"Front. Pharmacol."},{"key":"26956_CR19","doi-asserted-by":"publisher","unstructured":"Zhang, F. et al. Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 24 https:\/\/doi.org\/10.1007\/s00432-023-04589-2 (2023 Feb). Epub ahead of print.","DOI":"10.1007\/s00432-023-04589-2"},{"issue":"10","key":"26956_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","volume":"20","author":"S Zaccara","year":"2019","unstructured":"Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell. Biol. 20 (10), 608\u2013624 (2019).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"1","key":"26956_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13046-019-1058-6","volume":"38","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21. J. Exp. Clin. Cancer Res. 38 (1), 101 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"27","key":"26956_CR22","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1038\/s41388-022-02370-2","volume":"41","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma. Oncogene 41 (27), 3570\u20133583 (2022).","journal-title":"Oncogene"},{"key":"26956_CR23","doi-asserted-by":"publisher","first-page":"822011","DOI":"10.3389\/fcell.2022.822011","volume":"10","author":"Z Gu","year":"2022","unstructured":"Gu, Z., Du, Y., Zhao, X., Wang, C. & Diagnostic Therapeutic, and prognostic value of the m6A writer complex in hepatocellular carcinoma. Front. Cell. Dev. Biol. 10, 822011 (2022).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"26956_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-020-00453-8","volume":"6","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. HIF-1\u03b1-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal. Transduct. Target. Ther. 6 (1), 76 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"26956_CR25","doi-asserted-by":"publisher","first-page":"216122","DOI":"10.1016\/j.canlet.2023.216122","volume":"559","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 559, 216122 (2023).","journal-title":"Cancer Lett."},{"issue":"7743","key":"26956_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","volume":"566","author":"D Han","year":"2019","unstructured":"Han, D. et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 566 (7743), 270\u2013274 (2019).","journal-title":"Nature"},{"issue":"2","key":"26956_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41590-022-01398-6","volume":"24","author":"S Ma","year":"2023","unstructured":"Ma, S. et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8\u2009+\u2009T cells. Nat. Immunol. 24 (2), 255\u2013266 (2023).","journal-title":"Nat. Immunol."},{"issue":"1","key":"26956_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-021-01447-y","volume":"21","author":"W Wan","year":"2022","unstructured":"Wan, W. et al. METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol. Cancer. 21 (1), 60 (2022).","journal-title":"Mol. Cancer"},{"key":"26956_CR29","doi-asserted-by":"publisher","first-page":"102338","DOI":"10.1016\/j.coi.2023.102338","volume":"83","author":"DE Ramirez","year":"2023","unstructured":"Ramirez, D. E., Mohamed, A., Huang, Y. H. & Turk, M. J. In the right place at the right time: tissue-resident memory T cells in immunity to cancer. Curr. Opin. Immunol. 83, 102338 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"26956_CR30","doi-asserted-by":"publisher","first-page":"1149622","DOI":"10.3389\/fimmu.2023.1149622","volume":"14","author":"JT Ding","year":"2023","unstructured":"Ding, J. T. et al. Landscapes and mechanisms of CD8\u2009+\u2009T cell exhaustion in Gastrointestinal cancer. Front. Immunol. 14, 1149622 (2023).","journal-title":"Front. Immunol."},{"key":"26956_CR31","doi-asserted-by":"publisher","first-page":"114824","DOI":"10.1016\/j.biopha.2023.114824","volume":"163","author":"K Mortaezaee","year":"2023","unstructured":"Mortaezaee, K. & Majidpoor, J. Mechanisms of CD8\u2009+\u2009T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1. Biomed. Pharmacother. 163, 114824 (2023).","journal-title":"Biomed. Pharmacother"},{"issue":"1","key":"26956_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1186\/s12885-022-09872-y","volume":"22","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Zou, J. & Chen, R. An M0 macrophage-related prognostic model for hepatocellular carcinoma. BMC Cancer. 22 (1), 791 (2022).","journal-title":"BMC Cancer"},{"issue":"2","key":"26956_CR33","doi-asserted-by":"publisher","first-page":"e85841","DOI":"10.1172\/jci.insight.85841","volume":"1","author":"K Gabrusiewicz","year":"2016","unstructured":"Gabrusiewicz, K. et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 1 (2), e85841 (2016).","journal-title":"JCI Insight"},{"issue":"8","key":"26956_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Herv\u00e1s-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 525\u2013543 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"26956_CR35","first-page":"261","volume":"15","author":"YJ Liu","year":"2022","unstructured":"Liu, Y. J. et al. DNTTIP2 expression is associated with macrophage infiltration and malignant characteristics in Low-Grade glioma. Pharmgenomics Pers. Med. 15, 261\u2013275 (2022).","journal-title":"Pharmgenomics Pers. Med."},{"key":"26956_CR36","doi-asserted-by":"publisher","first-page":"109426","DOI":"10.1016\/j.abb.2022.109426","volume":"730","author":"J Bang","year":"2022","unstructured":"Bang, J. et al. SEPHS1: its evolution, function and roles in development and diseases. Arch. Biochem. Biophys. 730, 109426 (2022).","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"26956_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40164-021-00212-7","volume":"10","author":"S Yang","year":"2021","unstructured":"Yang, S. et al. SEPHS1 promotes SMAD2\/3\/4 expression and hepatocellular carcinoma cells invasion. Exp. Hematol. Oncol. 10 (1), 17 (2021).","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"26956_CR38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/cas.15242","volume":"113","author":"C Wu","year":"2022","unstructured":"Wu, C. et al. TCOF1 coordinates oncogenic activation and rRNA production and promotes tumorigenesis in HCC. Cancer Sci. 113 (2), 553\u2013564 (2022).","journal-title":"Cancer Sci."},{"issue":"6","key":"26956_CR39","first-page":"1417","volume":"37","author":"N Ohtomo","year":"2010","unstructured":"Ohtomo, N. et al. Expression of \u03b1-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor. Int. J. Oncol. 37 (6), 1417\u20131423 (2010).","journal-title":"Int. J. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26956-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26956-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26956-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T15:48:16Z","timestamp":1764258496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26956-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26956"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26956-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted and all experiments were performed in accordance with the provisions and tenets of the Declaration of Helsinki. The study was approved by the Ethics Committee of Renmin Hospital of Wuhan University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"42530"}}